Recruiting
Phase 2

NNC0662-0419

Sponsor:

Novo Nordisk A/S

Code:

NCT07639021

Conditions

Obesity

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NNC0662-0419

Semaglutide

NNC0662-0419 Placebo

Semaglutide placebo

Study Details

Brief summary:

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Conditions

Obesity

Study ID

NCT07639021

Start date

Jun 9, 2026

Status verified date

Jul, 2026

Completion date

Jul 12, 2027

Anticipated

Primary completion date

Jul 12, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the informed consent.
  • Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening.
  • Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

Exclusion Criteria:

  • Known or suspected hypersensitivity to study intervention(s) or related products.
  • Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
  • Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus.

Study Design

Enrollment

230 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: NNC0662-0419

Participants will receive NNC0662-0419 administered subcutaneously in a dose-escalation manner.

placebo comparator: NNC0662-0419 placebo

Participants will receive NNC0662-0419 placebo administered subcutaneously in a dose-escalation manner.

experimental: Semaglutide

Participants will receive semaglutide administered subcutaneously in a dose-escalation manner.

placebo comparator: Semaglutide placebo

Participants will receive semaglutide placebo administered subcutaneously in a dose-escalation manner.

Interventions

NNC0662-0419

NNC0662-0419 will be administered subcutaneously.

Semaglutide

Semaglutide will be administered subcutaneously.

NNC0662-0419 Placebo

Placebo matched to NNC0662-0419 will be administered subcutaneously.

Semaglutide placebo

Placebo matched to semaglutide will be administered subcutaneously.

Primary outcome measure

  • Number of gastrointestinal adverse events [ Time Frame: From week 0 to week 39 ]

Central Contacts and Locations

Central contacts

Novo Nordisk

(+1) 866-867-7178clinicaltrials@novonordisk.com

Locations

Chambliss Clinical Trials, LLC

Recruiting

Montgomery, Alabama, United States, 36106

FDRC

Recruiting

Costa Mesa, California, United States, 92627

Los Angeles Institute for Metabolic Research

Recruiting

Los Angeles, California, United States, 90015

Encore Medical Research LLC

Recruiting

Hollywood, Florida, United States, 33024

South Broward Research LLC

Recruiting

Miramar, Florida, United States, 33027

West Orange Endocrinology

Recruiting

Ocoee, Florida, United States, 34761

Cedar-Crosse Research Center

Recruiting

Chicago, Illinois, United States, 60607

Great Lakes Clinical Trials

Recruiting

Chicago, Illinois, United States, 60640

L-MARC Research Center

Recruiting

Louisville, Kentucky, United States, 40213

Endo And Metab Cons

Recruiting

Rockville, Maryland, United States, 20852

StudyMetrix Research LLC

Recruiting

City of Saint Peters, Missouri, United States, 63303

Great Lakes Medical Research

Recruiting

Westfield, New York, United States, 14787

KDCILM, LLC & Accellacare US, Inc.

Recruiting

Wilmington, North Carolina, United States, 28401

Family Practice Center of Wadsworth Inc.

Recruiting

Wadsworth, Ohio, United States, 44281-9236

UPA Ctr Weight and Eating Dis

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Clinical Res Collaborative

Recruiting

Cumberland, Rhode Island, United States, 02864

Holston Medical Group_Bristol

Recruiting

Bristol, Tennessee, United States, 37620

Holston Medical Group

Recruiting

Kingsport, Tennessee, United States, 37660

Clinical Research Associates

Recruiting

Nashville, Tennessee, United States, 37203

PlanIt Research, PLLC

Recruiting

Houston, Texas, United States, 77079

Pinnacle Clinical Research

Recruiting

San Antonio, Texas, United States, 78222

National Clin Res Inc.

Recruiting

Richmond, Virginia, United States, 23294

Rainier Clin Res Ctr Inc

Recruiting

Renton, Washington, United States, 98057

More Information

Sponsor

Novo Nordisk A/S

Last update posted

Jul 10, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Novo Nordisk A/S on 2026-07-10.